Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00601107 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis

A Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis, sponsored by Genzyme, a Sanofi Company.

Completed
Registry status
Phase 2
Development phase
111
Enrollment target
19
Study locations

NCT00601107 is a Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 111 participants, below the 191-participant average among 3 other Moderate-to-severe Chronic Plaque Psoriasis trials with a reported enrollment target (42% lower). The trial reports 19 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00601107, a Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis, has completed, sponsored by Genzyme, a Sanofi Company.

COMPLETED
Registry status
Phase 2
Development phase
111 participants
Enrollment target
19
Study locations

Study Summary

The purpose of this study was to evaluate the safety and effectiveness of an investigational drug called doxercalciferol in participants with moderate to severe chronic plaque psoriasis, in comparison with a placebo ("sugar pill"). All study related care was provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation was 28 weeks.

Conditions Studied

Moderate-to-severe Chronic Plaque Psoriasis

Interventions

  • DRUG Placebo
  • DRUG Doxercalciferol

Study Locations (19)

California

  • - Irvine
  • - Santa Monica

Massachusetts

  • - Andover
  • - Boston

Michigan

  • - Troy
  • - West Bloomfield

Alabama

  • - Birmingham

Arizona

  • - Hot Springs

Arkansas

  • - Little Rock

Georgia

  • - Alpharetta

Indiana

  • - Indianapolis

Trial Details

FieldValue
Enrollment Target 111 participants
Start Date 2008-04
Est. Completion 2009-06
Phase Phase 2

Sponsor

Genzyme, a Sanofi Company

196 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00601107

The ClinicalTrials.gov registry entry for NCT00601107 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 191-participant average among 3 other Moderate-to-severe Chronic Plaque Psoriasis trials with a reported enrollment target (42% lower). The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Moderate-to-severe Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00601107 reports 19 study locations spanning 16 distinct geographic areas - top geographies include California, Massachusetts, Michigan.

Frequently Asked Questions

What is clinical trial NCT00601107 about?

NCT00601107 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis". The purpose of this study was to evaluate the safety and effectiveness of an investigational drug called doxercalciferol in participants with moderate to severe chronic plaque psoriasis, in comparison with a placebo ("sugar pill"). All study related care was provided including doctor visits, physica...

What is the current status of trial NCT00601107?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2008-04. Estimated completion is 2009-06.

What conditions does trial NCT00601107 study?

This clinical trial studies the following conditions: Moderate-to-severe Chronic Plaque Psoriasis.

What interventions are being tested in trial NCT00601107?

The interventions under investigation include: Placebo (DRUG), Doxercalciferol (DRUG).

Who is sponsoring clinical trial NCT00601107?

This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00601107 being conducted?

This trial has 19 study locations across Alabama, Arizona, Arkansas, California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Moderate-to-severe Chronic Plaque Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Moderate-to-severe Chronic Plaque Psoriasis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.